SCYX

SCYNEXIS, Inc. Common Stock

$3.96

Current Price

All

AI analysis

Read what the AI thinks of SCYNEXIS, Inc. Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$2.16

P/E

—

Data as of Oct 1

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$0.63

Nov 11

Posts

No posts about SCYX yet.

About SCYNEXIS, Inc. Common Stock

SCYNEXIS is a small biopharmaceutical company focused on fungal infections. Its main product, ibrexafungerp, is sold under the brand name Brexafemme as a treatment for vaginal yeast infections and is also being tested as a treatment for more dangerous fungal infections in hospitalized patients. The company makes money through direct product sales plus royalty and milestone payments from larger drugmakers it has licensed the drug to in other regions.